Roche Tasmar Sales Are Over $20 Mil. Worldwide Since August Launch
Executive Summary
Roche's sales of the Parkinson's therapy Tasmar (tolcapone) have exceeded $20 mil. (CHF 30 mil.) worldwide since the product was first launched in August, CEO Franz Humer reported at the firm's annual media conference in Basel, Switzerland April 7.